Compare Incyte Corporation (INCY) vs McCormick & Company, Incorporated (MKC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs McCormick & Company, Incorporated — how do they compare? Incyte Corporation trades at $115.71 (market cap $23.11B), while McCormick & Company, Incorporated trades at $52 (market cap $14.04B). The key difference: Incyte Corporation is the larger of the two by market cap, and McCormick & Company, Incorporated pays a 3.68% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | MKC | |
|---|---|---|
Market Cap | $23.11B | $14.04B |
Sector | Health | Consumer Staples |
52-Week High | $118.52 | $72.81 |
52-Week Low | $67.38 | $45.60 |
Enterprise Value | $19.13B | $18.65B |
Dividend Yield | — | 3.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
MKC trades at $52.26, up 1.08% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows strong profitability with a 21.91% net income margin and a low P/E of 8.6, suggesting potential undervaluation. Recent Q2 2026 earnings beat expectations, and the pending Unilever Foods deal is a key strategic focus. Cash flow from operations remains robust at $962.2 million for 2025, though net cash flow was negative $90.2 million due to financing activities.
The outlook is mixed; analyst consensus is a buy with a $59.67 price target, implying 14% upside, but technicals and modest organic growth pose risks. The transformative Unilever deal offers growth potential, yet execution risks and competitive pressures in consumer segments warrant caution. Debt reduction trends are positive, with debt-to-asset ratio improving to 30.34% in 2025.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →
